Your guide to a COVID-19 vaccine: What the public needs to know

Keck Medicine of USC

News about a potential COVID-19 vaccine is announced almost daily, leading people to wonder when will a vaccine will be available, and whether it will be safe. Edward Jones-Lopez, MD, MS, a Keck Medicine of USC infectious diseases expert and investigator of one of the Operation Warp Speed vaccine clinical trials, answers the questions on everyone’s mind.

How many potential COVID-19 vaccines are there?

Currently there are some 45 vaccine candidates testing in human clinical trials in addition to many being tested in animals. Researchers are using a wide variety of approaches to potentially stimulate an immune response in the body to protect against SARS-CoV-2, the virus that causes COVID-19. The most common type of vaccine candidate contains a virus that has been genetically engineered with coronavirus genes to provoke the intended immune response. 

Can you explain the different phases of COVID-19 vaccine clinical trials?

After initial laboratory and animal testing is completed, vaccine candidates enter a phase 1 human clinical trial, where a small group of people (10-50) receive the trial vaccine to determine the dosing of a potential vaccine, potential side effects of the administration of the vaccine and safety of the vaccine. Phase 2 expands to hundreds of volunteers where we continue to test a vaccine for safety and collect early data about the vaccine’s potential efficacy.

In phase 3, the trial expands to tens of thousands of people to measure if the vaccine offers protection against SARS-CoV-2 infection or severe disease, and to continue to focus on safety in a diverse population. In the United States, the Food and Drug Administration (FDA) will approve a COVID-19 vaccine only after a successful phase 3 trial. Several potential COVID-19 vaccines are currently in phase 3 clinical trials, each including 30,000 or more volunteers.

How do Phase 3 clinical trials for potential COVID-19 vaccines work?

In these trials, one group of volunteers is randomly selected to receive the experimental vaccine, while another receives the placebo. Researchers then compare how many of those who were vaccinated become infected or ill with the coronavirus versus those who received a placebo. The FDA has determined that a COVID-19 vaccine must be at least 50% effective in preventing COVID-19 or, should someone contract the disease, in protecting against a serious case of COVID-19.

The trials are targeting high-risk-groups more likely to contract the virus or have severe complications to drive outcomes and get quicker results.   

When will a vaccine be available and how effective will it be?

Some phase 3 COVID-19 vaccine clinical trials are getting close to completing the enrollment of volunteers. We could see one or more vaccines become available three to six months after the completion of a trial’s enrollment, which could be as soon as early next year.

It’s likely that people may need to be vaccinated each year, just as for the flu, but we don’t know for sure yet. 

Vaccines typically take five to seven years to be developed.  How is one for COVID-19 being developed so quickly and how can we know it’s safe?

We are benefitting from previous work done over the last decades to find safe, effective vaccines faster. In addition, the manufacturing of a vaccine traditionally begins after the vaccine has been approved through a phase 3 clinical trial. However, given the global emergency related to COVID-19, several state and private entities in the world have agreed to cover the costs of manufacturing millions of doses of potential COVID-19 vaccines during the clinical trials, shaving years off the process.

Despite the speed of development, scientists are adhering to the same rigid safety protocols for a COVID-19 vaccine that have been followed for all other previously approved vaccines and have proven to be safe, in some cases after several decades of use. 

If someone is interested in volunteering for a trial, can they still participate?

Some half a million Americans have signed up to be part of a COVID-19 clinical trial, but more volunteers are needed to complete the trials, including people from high-risk populations and underserved communities. Anyone wishing to volunteer can register at

Editor’s Note: Keck Medicine of USC is involved in an international phase 3 clinical trial for a COVID-19 vaccine sponsored by AstraZeneca and the University of Oxford.


For more information about Keck Medicine of USC, please visit


Filters close

Showing results

110 of 4219
Released: 4-Dec-2020 4:30 PM EST
New review confirms disproportionate impact of COVID-19 on Black, Hispanic populations
Oregon Health & Science University

Black and Hispanic populations are disproportionately affected by COVID-19, according to a systematic review published this week.

Newswise: 250647_web.jpg
Released: 4-Dec-2020 4:05 PM EST
For nationalistic regimes, similar COVID-19 policies are the sincerest form of flattery
University of Texas at Arlington

Analysis from a University of Texas at Arlington assistant professor of public policy suggests that nationalistic governments around the globe are more likely to copy other nationalistic governments in responding to the current pandemic.

Released: 4-Dec-2020 3:15 PM EST
New Study Finds Once Hospitalized, Black Patients with COVID-19 Have Lower Risk of Death than White Patients
NYU Langone Health

A team of investigators at NYU Langone Health has found that once hospitalized, Black patients (after controlling for other serious health conditions and neighborhood income) were less likely to have severe illness, die, or be discharged to hospice compared to White patients.

Released: 4-Dec-2020 2:35 PM EST
AANA Commends CDC on Prioritizing COVID-19 Vaccine Distribution to Healthcare Personnel
American Association of Nurse Anesthetists (AANA)

The American Association of Nurse Anesthetists (AANA) commends the U.S. Centers for Disease Control and Prevention’s (CDC's) team of advisors on prioritizing frontline healthcare personnel and residents of long-term facilities for the first phase of the COVID-19 vaccine distribution.

Released: 4-Dec-2020 1:50 PM EST
COVID-19 in Victorian schools and childcare mainly driven by community transmission
Murdoch Childrens Research Institute

Analysis of Victorian data by the Murdoch Children's Research Institute suggests that COVID-19 cases in schools and childcare were mainly driven by community transmission

Released: 4-Dec-2020 12:20 PM EST
Identifying markers of COVID-19 infection using blood tests
University of Seville

Researchers from the Institute of Biomedicine of Seville (IBIS) have presented a study carried out in the Clinical Biochemistry Service of the Virgen del Rocío University Hospital which identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19).

Released: 4-Dec-2020 12:05 PM EST
Research confirms crucial monitoring assessment is effective for patients with COVID-19
University of Portsmouth

A combined research team from the Universities of Portsmouth and Bournemouth and Portsmouth Hospitals University NHS Trust has shown that an assessment score used to measure a patient's severity of illness can be applied to patients with Covid-19 without modification.

Newswise:Video Embedded flccc-alliance-calls-on-national-health-authorities-to-immediately-review-medical-evidence-showing-the-efficacy-of-ivermectin-for-the-prevention-of-covid-19-and-as-an-early-outpatient-treatment
Released: 4-Dec-2020 12:00 PM EST
FLCCC Alliance Calls on National Health Authorities to Immediately Review Medical Evidence Showing the Efficacy of Ivermectin for the Prevention of COVID-19 and as an Early Outpatient Treatment
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

“Following the swi. review— and subsequent guidance— by the NIH and theCDC of Ivermectin, we expect that Ivermectin’s widespread, immediate use willallow for a rapid and safe re-opening of businesses and schools across the nation—and quickly reduce the strain on overwhelmed ICUs.” —FLCCC Alliance

Released: 4-Dec-2020 11:50 AM EST
Immunity passports: Ethical conflict and opportunity
University of the Basque Country

Immunity passports are a means of registering whether an individual has developed immunity to COVID-19 and is therefore unlikely to either catch or spread the disease.

Showing results

110 of 4219